TD Cowen raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $49 and keeps a Buy rating on the shares. The firm come away positive from investor day, where management introduced a 15-20% organic EBITDA CAGR target for 2026-2028. While they reiterated their view that 2026 guide is conservative, the bigger takeaway is that tailwinds should continue beyond 2028.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $52 from $50 at Mizuho
- BrightSpring: Specialty Pharmacy Growth, Structural Tailwinds, and Upside to Long-Term EBITDA Targets Support Buy Rating
- BrightSpring: Diversified Growth and Attractive Valuation Underpin Buy Rating
- BrightSpring (BTSG): Gaining Share in Lower-Cost Post-Acute Care with Strong Segment Momentum and Margin Upside Supporting $55 Target
- BrightSpring Announces Secondary Offering and Share Repurchase Plan